Key Drivers
- Strong liquidity
- Persistent losses
- Rich valuation
AIAI Summary
Protagonist's profile has shifted from binary R&D risk to a partner‑milestone and royalty‑driven cash‑flow story—meaning the stock's near‑term re‑rating now hinges on J&J milestone receipts and the Q2 rusfertide opt‑out economics rather than internal trial readouts. Actionable focus: monitor milestone cash inflows, the timing/terms of the rusfertide opt‑out decision, and quarterly operating cash flow for signs the market‑priced commercialization outcomes are being realized.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Persistent losses
- •Rich valuation
PTGX has strong liquidity and negligible leverage providing runway, but persistent operating losses, heavy R&D/opex relative to revenue, and an elevated market valuation create substantial execution and valuation risk.
Price Behavior
Key Price Behavior Insights:
- •Above last month SMA
- •Low-90s support
- •Resistance $101.68
PTGX is in a short-term uptrend above its last month SMA (~$93.2) after higher highs/lows from $82.76, with primary support in the low-$90s ($91–$93) and near-term resistance at $101.68—holding the low-$90s favors continuation, while a break below ~$91 or failure to clear $101.68 increases pullback risk.
Elevated day-to-day volatility and a single-day reversal from $101.68 on 2026-03-20, showing quick profit‑taking risk
Sentiment & News
Key News Insights:
- •Rusfertide Priority
- •ICOTYDE milestone
- •Institutional shifts
Protagonist's regulatory momentum—rusfertide FDA Priority Review and ICOTYDE-triggered milestones—plus pipeline progress and shifting institutional ownership drove a notable share-volume and sentiment uptick.
These developments de-risk near-term commercial and cash milestones, likely supporting upside in the stock if rusfertide's PDUFA and royalty/milestone flows materialize
Similar Companies in Healthcare
Other companies in the same sector with AI ratings